Immunocore Signals Major Corporate Event via SEC Filings

TL;DR

**Immunocore's 8-K hints at a big corporate move, likely M&A or tender offer, impacting IMCR shares.**

AI Summary

Immunocore Holdings plc filed an 8-K on January 2, 2024, indicating that it is making written communications pursuant to Rule 425 under the Securities Act, soliciting material pursuant to Rule 14a-12 under the Exchange Act, and pre-commencement communications under Rules 14d-2(b) and 13e-4(c). This filing signals that Immunocore is likely involved in a significant corporate event, such as a merger, acquisition, or tender offer, which requires specific communications to shareholders and the public. For investors, this matters because such events can significantly impact the company's valuation, future prospects, and the value of their American Depositary Shares (IMCR) traded on The Nasdaq Stock Market LLC.

Why It Matters

This filing indicates Immunocore is engaging in communications related to a potential significant corporate transaction, which could lead to substantial changes in the company's structure or ownership and directly affect stock value.

Risk Assessment

Risk Level: medium — The filing signals an ongoing corporate event, which inherently carries execution risk and potential for stock price volatility, making it a medium risk.

Analyst Insight

A smart investor would monitor Immunocore's subsequent filings and press releases closely for details on the corporate event, as this could significantly impact the stock price. Consider the potential upside or downside of a merger or acquisition before making any trading decisions.

Key Players & Entities

• Immunocore Holdings plc (company) — registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — exchange where American Depositary Shares (IMCR) are registered
• American Depositary Shares (other) — securities registered pursuant to Section 12(b) of the Act
• IMCR (other) — trading symbol for American Depositary Shares
• January 2, 2024 (date) — date of earliest event reported and filing date

Forward-Looking Statements

• Immunocore Holdings plc will announce details of a merger, acquisition, or tender offer. (Immunocore Holdings plc) — medium confidence, target: Q1 2024

FAQ

Filing Documents

• ef20017537_8k.htm (8-K) — 33KB
• 0001140361-24-000012.txt ( ) — 202KB
• imcr-20240102.xsd (EX-101.SCH) — 4KB
• imcr-20240102_def.xml (EX-101.DEF) — 17KB
• imcr-20240102_lab.xml (EX-101.LAB) — 26KB
• imcr-20240102_pre.xml (EX-101.PRE) — 19KB
• ef20017537_8k_htm.xml (XML) — 6KB

01

Item 7.01. Regulation FD Disclosure. Domestic Issuer Status Effective January 1, 2024, Immunocore Holdings plc (the "Company") will begin to file periodic reports and registration statements on U.S. domestic issuer forms with the U.S. Securities and Exchange Commission, which are more detailed and extensive in certain respects, and which must be filed more promptly, than the forms available to a "foreign private issuer" as defined in Rule 405 under the Securities Act of 1933, as amended. Prior to January 1, 2024, the Company qualified as a foreign private issuer. Disclosure Channels to Disseminate Information The Company announces material information to the public about the Company, its product KIMMTRAK, its potential product candidates, its pipeline and the Company's IMMTAX platform and other matters through a variety of means, including filings with the U.S. Securities and Exchange Commission, press releases, public conference calls, the Company's website (www.immunocore.com), the investor relations section of its website (ir.immunocore.com), and/or social media, including its LinkedIn account (www.linkedin.com/company/immunocore) and X account (formerly known as "Twitter") (@Immunocore), in order to achieve broad, non-exclusionary distribution of information to the public. The Company encourages investors and others to review the information it makes public in these locations, as such information could be deemed to be material information. Please note that this list may be updated from time to time.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOCORE HOLDINGS PLC Dated: January 2, 2024 By: /s/ Bahija Jallal, Ph.D. Name: Bahija Jallal, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR